Citizens JMP analyst Reni Benjamin raised the firm’s price target on Bicycle Therapeutics (BCYC) to $12 from $10 and keeps an Outperform rating on the shares. Bicycle reported Q3 financial results and updated corporate milestones, including regulatory feedback regarding dose selection for the pivotal Duravelo-2 now expected in 1Q26, the analyst tells investors in a research note. Bicycle shares have upside from current levels, with the zele pivotal trial enrolling, multiple partnerships secured, and a strong cash position of $648.3M, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- RBC downgrades Bicycle Therapeutics on slow pipeline progress
- Bicycle Therapeutics Reports Q3 2025 Financial Results
- Bicycle Therapeutics downgraded to Sector Perform at RBC Capital
- Strategic Regulatory Alignment and Positive Momentum Justify Buy Rating for Bicycle Therapeutics
- Bicycle Therapeutics reports Q3 EPS (85c), consensus ($1.07)